Pazopanib vs Placebo in Patients With Metastatic Renal Cell Carcinoma With No Evidence of Disease After Metastasectomy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810
J. Clin. Oncol 2024 Mar 26;[EPub Ahead of Print], LJ Appleman, SE Kim, WB Harris, SK Pal, MR Pins, J Kolesar, N Agarwal, RA Parikh, DA Vaena, CW Ryan, M Hashmi, BA Costello, D Cella, JP Dutcher, RS DiPaola, NB Haas, LI Wagner, MA CarducciFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.